(Q35906110)

11 August 2017

1 reference

title

Bradykinin receptor ligands: therapeutic perspectives (English)

1 reference

11 August 2017

2

Domenico Regoli

1 reference

11 August 2017

1

François Marceau

1 reference

11 August 2017

1 October 2004

1 reference

Nature Reviews Drug Discovery

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

10

1 reference

11 August 2017

845-852

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1522

11 August 2017

0 references

cites work

The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins.

1 reference

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

31 March 2020

1 reference

Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men

31 March 2020

1 reference

Expression cloning of a rat B2 bradykinin receptor

31 March 2020

1 reference

Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons.

31 March 2020

1 reference

Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors

31 March 2020

1 reference

Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors

31 March 2020

1 reference

Structure of the mammalian kinin receptor gene locus

31 March 2020

1 reference

Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension

31 March 2020

1 reference

Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists

31 March 2020

1 reference

Discovery of a potent, non-peptide bradykinin B1 receptor antagonist

31 March 2020

1 reference

SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the brady

31 March 2020

1 reference

Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core

31 March 2020

1 reference

The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation

31 March 2020

1 reference

Targeting kinin B(1) receptor for therapeutic neovascularization

31 March 2020

1 reference

Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor

31 March 2020

1 reference

Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease

31 March 2020

1 reference

Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease

31 March 2020

1 reference

Mediators of bradykinin-induced vasorelaxation in human coronary microarteries

31 March 2020

1 reference

Up-regulation of functional kinin B1 receptors in allergic airway inflammation.

31 March 2020

1 reference

Kinin B1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx

31 March 2020

1 reference

Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury

31 March 2020

1 reference

Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation

31 March 2020

1 reference

Agonist-induced translocation of the kinin B(1) receptor to caveolae-related rafts.

31 March 2020

1 reference

Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin

31 March 2020

1 reference

Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin

31 March 2020

1 reference

The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.

31 March 2020

1 reference

AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism

31 March 2020

1 reference

AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions

31 March 2020

1 reference

Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization.

31 March 2020

1 reference

Kinin B1 receptor antagonists containing alpha-methyl-L-phenylalanine: in vitro and in vivo antagonistic activities

31 March 2020

1 reference

Kinin B1 receptor antagonists with multi-enzymatic resistance properties

31 March 2020

1 reference

New bradykinin antagonists having very high potency at B1 receptors

31 March 2020

1 reference

Competitive antagonists of bradykinin

31 March 2020

1 reference

Bradykinin antagonists: discovery and development

31 March 2020

1 reference

Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies

31 March 2020

1 reference

The identification of an orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657

31 March 2020

1 reference

Pharmacological profile of LF 16-0687, a new potent non-peptide bradykinin B2 receptor antagonist

31 March 2020

1 reference

Effects of the non-peptide B2 receptor antagonist FR173657 in models of visceral and cutaneous inflammation

31 March 2020

1 reference

Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat.

31 March 2020

1 reference

Contribution of B(2) receptors for bradykinin in arthus reaction-induced plasma extravasation in wild-type or B(2) transgenic knockout mice

31 March 2020

1 reference

LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats

31 March 2020

1 reference

Effects of LF 16-0687 Ms, a bradykinin B(2) receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia

31 March 2020

1 reference

Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127.

31 March 2020

1 reference

Implication of the bradykinin receptors in antigen‐induced pulmonary inflammation in mice

31 March 2020

1 reference

Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia

31 March 2020

1 reference

Increased mRNA expression of the B1 and B2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain

31 March 2020

1 reference

Basal expression of bradykinin B(1) receptor in the spinal cord in humans and rats

31 March 2020

1 reference

Bradykinin B1 receptor is constitutively expressed in the rat sensory nervous system

31 March 2020

1 reference

Autoradiographic analysis of rat brain kinin B1 and B2 receptors: normal distribution and alterations induced by epilepsy

31 March 2020

1 reference

Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy.

31 March 2020

1 reference

Generation and characterization of a human bradykinin receptor B1 transgenic rat as a pharmacodynamic model

31 March 2020

1 reference

Role of bradykinin B(1) receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice

31 March 2020

1 reference

Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I

31 March 2020

1 reference

ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO.

31 March 2020

1 reference

Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics

31 March 2020

1 reference

Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

The involvement of kallikrein-kinin system in diabetes type I (insulitis)

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1522

1 reference

PubMed ID

15459675

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15459675